A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer
Daniel A. Goldstein; Noa Gordon; Michal Davidescu; Moshe Leshno; Conor E. Steuer; Nikita Patel; Salomon M. Stemmer; Alona Zer
Author Information: Davidoff Cancer Center, Rabin Medical Center, Petach Tikvah, Israel (DAG, NG, SMS, AZ); Winship Cancer Institute, Emory University, Atlanta, GA (DAG, CES, NP); Ben Gurion University of the Negev, Beer Sheva, Israel (NG); Clalit Health Services Headquarters, Tel Aviv, Israel (MD); Sackler Faculty of Medicine (ML, SMS, AZ) and Faculty of Management (ML), Tel Aviv University, Tel Aviv, Israel
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.